Moderna, Inc.

NASDAQ:MRNA

Biotechnology

Healthcare
$196.79 +4.01%

+$2.48 today

Market cap
$79.63B
Beta
1.03
P/E (TTM)
-7.9
EPS (TTM)
-$8.09
52W Low $22.28High $67.74

Volume 6.91M

Average 6.53M

MRNA Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Moderna, Inc.NASDAQ: MRNA

Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026

Accounts receivables growth accelerates

Q3 FY2026 accounts receivables of $1.35B (cash outflow) rose 33.4% year over year, ahead of the -164.6% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -55.7% a year.

Context

  • Accounts receivables amounted to 8.0% of revenue in FY2025, down 8.7 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +33.4% holds above the trailing-twelve-month pace of -164.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$1.35B-2649.1% QoQ
Last fiscal yearDec 2025
$156M-70.8% YoY
LTMSep 2026
-$325M-164.6% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+33.4%——
1 year-70.8%——
3-year CAGR-55.7%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
156M USD
Year-over-year change
-70.8%

Accounts Receivables vs competitors

How MRNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -164.6% is the lowest of 7, against a peer median of +53.3%.
  • Accounts receivables amounts to 12.9% of revenue for MRNA, versus a peer median of 0.0%.
MRNA Competitors
Accounts Receivables for MRNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€1.89B EUR+210.6%-38.0%71.6%
MRNAModerna, Inc.LTM Sep 2026$325M USD-164.6%-55.7%12.9%
NVAXNovavax, Inc.LTM Mar 2026$73.42M USD-44.3%-37.4%12.3%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$13.31M USD+6.6%—29.4%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$331.65K USD-73.3%——
PFEPfizer Inc.LTM Jun 2026$0 USD——0.0%
GSKGSK plcLTM Jun 2026£0 GBP——0.0%
PCVXVaxcyte, Inc.LTM Jun 2026$0 USD———
VIRVir Biotechnology, Inc.LTM Mar 2026$0 USD+100.0%—0.0%
VALNValneva SELTM Mar 2026€0 EUR+100.0%+2.4%0.0%
Peer median (excluding MRNA) —+53.3%-37.4%0.0%

Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income12.2B8.36B(4.71B)(3.56B)(2.82B)
Depreciation & Amortization232M348M621M189M215M
Deferred Income Tax(318M)(559M)828M00
Stock-Based Compensation142M226M305M429M483M
Change in Working Capital1.31B(3.46B)(139M)(78M)254M
Accounts Receivables(1.78B)1.79B493M534M156M
Inventory(1.39B)492M747M83M(34M)
Accounts Payables204M240M13M(69M)(92M)
Other Working Capital4.28B(5.98B)(1.39B)(626M)224M
Other Non-Cash Items54M59M(19M)17M(3M)
Operating Cash Flow13.62B4.98B(3.12B)(3B)(1.87B)
Capital Expenditures(284M)(400M)(707M)(1.05B)(192M)
Acquisitions (Net)00(85M)00
Purchases of Investments(12.65B)(11.44B)(3.78B)(6.53B)(5.77B)
Sales of Investments4.44B6.7B8.78B9.53B7.92B
Other Investing Activities(30M)(40M)00(10M)
Investing Cash Flow(8.52B)(5.18B)4.21B1.95B1.95B
Debt Repayment(140M)(184M)(270M)(10M)539M
Common Stock Issued124M65M46M66M35M
Common Stock Repurchased(857M)(3.33B)(1.15B)00
Dividends Paid00000
Other Financing Activities000019M
Financing Cash Flow(873M)(3.45B)(1.38B)56M593M
Effect of Forex Changes00002M
Net Change in Cash4.22B(3.64B)(289M)(999M)668M
Free Cash Flow13.34B4.58B(3.83B)(4.06B)(2.07B)

Moderna, Inc.

NASDAQ:MRNA

Intrinsic Alpha fair value

Locked

Current Price

$196.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.